Amicus director exits stake in BioMarin merger
Amicus Therapeutics director Glenn Sblendorio disposed of his equity stake in connection with the company’s acquisition by BioMarin Pharmaceutical.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Amicus Therapeutics director Glenn Sblendorio disposed of his equity stake in connection with the company’s acquisition by BioMarin Pharmaceutical. He surrendered 142,564 shares of Common Stock at $14.50 per share and 20,414 restricted stock units that vested in full at the merger closing.
Multiple fully vested stock option grants covering shares of Common Stock were also cancelled. For each option, Mr. Sblendorio became entitled to a cash payment equal to the excess of $14.50 per share over the option’s exercise price, multiplied by the number of option shares. Following these transactions, the filing shows no remaining direct stock or option holdings.
Insider Trade Summary
Disposition: 446,194 shares
Disposition
10 txns
Insider
SBLENDORIO GLENN
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Options (right to buy) | 20,000 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 16,236 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 19,473 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 18,574 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 36,111 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 45,423 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 30,474 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 42,467 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 74,872 | $0.00 | $0.00 |
| Disposition | Common Stock | 142,564 | $14.50 | $2.07M |
Holdings After Transaction:
Stock Options (right to buy) — 0 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (4)
- F1. The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 122,150 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger).
- F2. In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option.
- F3. Each Option was fully vested.
- F4. Each Option vested in full in connection with consummation of the Merger.
Key Figures
Common shares disposed: 142,564 shares at $14.50
Merger cash price: $14.50 per share
Restricted stock units vested: 20,414 RSUs
+5 more
8 metrics
Common shares disposed
142,564 shares at $14.50
Common Stock surrendered at merger closing
Merger cash price
$14.50 per share
Cash consideration used for stock and options
Restricted stock units vested
20,414 RSUs
RSUs vested in full upon consummation of the Merger
Option tranche shares
74,872 shares
Stock options at $5.96 exercise price cancelled for cash
Option tranche shares
42,467 shares
Stock options at $10.27 exercise price cancelled for cash
Option tranche shares
45,423 shares
Stock options at $8.55 exercise price cancelled for cash
Smallest option tranche
16,236 shares
Stock options at $8.60 exercise price cancelled for cash
Derivative positions remaining
0 options
No remaining derivative holdings in derivativeSummary
Key Terms
restricted stock units, Merger, stock option, cash payment, +2 more
6 terms
restricted stock units financial
"20,414 restricted stock units (which vested in full in connection with consummation of the Merger)"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Merger financial
"disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger")"
A merger is when two companies combine into a single business, with ownership and control reorganized so they operate as one entity. For investors it matters because mergers can change the value and risk of holdings—shares may be exchanged, diluted, or rise if the combined company saves costs or gains market power, and the deal often depends on regulatory approval and successful integration like two households joining resources and routines.
stock option financial
"each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
cash payment financial
"converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share"
exercise price financial
"the excess of (i) $14.50 per share over (ii) the exercise price payable per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
fully vested financial
"Each Option was fully vested."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Glenn Sblendorio report at Amicus Therapeutics (FOLD)?
Glenn Sblendorio reported disposing of his Amicus Therapeutics equity in connection with its acquisition by BioMarin. He surrendered 142,564 common shares and fully vested equity awards in exchange for cash consideration based on the merger price of $14.50 per share.
What happened to Glenn Sblendorio’s Amicus Therapeutics (FOLD) stock options in the merger?
Each reported stock option was cancelled at closing and converted into a cash right. The cash equals $14.50 per share minus the option’s exercise price, multiplied by the number of underlying shares, with all options described as fully vested at consummation.
How were Glenn Sblendorio’s Amicus Therapeutics (FOLD) restricted stock units treated in the merger?
The filing states 20,414 restricted stock units vested in full upon consummation of the merger. These vested RSUs were included with his other equity in the overall cash consideration, using the same $14.50 per-share merger price outlined for common shares and options.
AI-generated analysis. How Rhea-AI works. Not financial advice.
